Resources

Your selections:

Clear all

Show Filters

We found 278 resources that match your search.

PGDM1400

Document Date:

PGDM1400LS (VRC-HIVMAB0112-00AB)

Document Date:

PGT121

Document Date:

PGT121.414.LS (VRC-HIVMAB0107-00-AB)

Document Date:

Pitavastatin (Livalo) Tablet Package Insert

LIVALO is a HMG-CoA reductase inhibitor indicated for: Patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase…

Document Date:

Pretomanid (PA-824)

Document Date:

Priftin (rifapentine) Tablets, Package Insert

PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more anti-tuberculosis (anti-TB) drugs to which the isolate is susceptible. (1.1) *…

Document Date:

Protocol Development Lifecycle Resource

Protocol Development Lifecycle flowchart

Document Date:

Protocol Registration at a Glance Quick Reference Card

Quick reference card for protocol registration at a glance.

Document Date:

Protocol Registration Checklist

Division of AIDS (DAIDS) protocol registration checklist. NOTE: This form is not required if submitting materials through the DAIDS Protocol Registration System (DPRS).

Document Date:

Protocol Registration Checklist (Alternate Format)

Division of AIDS (DAIDS) protocol registration checklist. NOTE: This form is not required if submitting materials through the DAIDS Protocol Registration System (DPRS).

Document Date:

Pyrazinamide Package Insert

Document Date:

Quick Reference Card - Adverse Event Checklist

Use this to make sure you don't miss any required pieces of information when recording and reporting an adverse event.

Document Date:

Quick Reference Card - Narrative Case Summary and AE/SAE/EAE Essentials

One-sheet references for writing a narrative case summary of an adverse event and for evaluation and follow-up.

Document Date:

Raltegravir (Isentress)

The following side effects have been associated with the use of raltegravir:

Document Date:

Raltegravir (Isentress)

Document Date:

Recombinant oligomeric gp145 C.6980 Clade C HIV Env protein

Document Date:

Relevant Communications and Vendor Oversight Communication

Document Date:

Remdesivir (Veklury)

Document Date:

Required Documentation Based on 45 CFR 46

Required documentation of risk/benefit category and approval of clinical studies for inclusion of children by institutional review boards/ethics committees based on 45 CFR 46, Subpart D.

Document Date:

Ribavirin

Document Date:

Ribavirin (Ribasphere) Package Insert

Ribasphere is a nucleoside analogue indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients…

Document Date:

Ribavirin Tablet, Package Insert

Ribavirin is a nucleoside analogue indicated for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in patients 5 years of age and older with compensated liver disease not previously treated with interferon alpha, and in adult CHC patients…

Document Date:

Rifabutin Package Insert

Document Date:

Rifafour e-276 (Rifampin/Isoniazid/Pyrazinamide/Ethambutol)

Document Date: